Combining CDP-choline and galantamine: Effects of a selective α7 nicotinic acetylcholine receptor agonist strategy on P50 sensory gating of speech sounds in healthy volunteers.
Adult
Cognition
/ drug effects
Cytidine Diphosphate Choline
/ therapeutic use
Double-Blind Method
Evoked Potentials
/ drug effects
Female
Galantamine
/ therapeutic use
Healthy Volunteers
Humans
Male
Nicotine
/ metabolism
Nicotinic Agonists
/ therapeutic use
Nootropic Agents
/ therapeutic use
Phonetics
Pilot Projects
Receptors, Nicotinic
/ metabolism
Schizophrenia
/ drug therapy
Sensory Gating
/ drug effects
Speech
/ drug effects
alpha7 Nicotinic Acetylcholine Receptor
/ agonists
CDP-choline
ERP
P50
P50 suppression
PAM
galantamine
schizophrenia
sensory gating
α7 nAChR
Journal
Journal of psychopharmacology (Oxford, England)
ISSN: 1461-7285
Titre abrégé: J Psychopharmacol
Pays: United States
ID NLM: 8907828
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
pubmed:
29
3
2019
medline:
24
6
2020
entrez:
29
3
2019
Statut:
ppublish
Résumé
Schizophrenia (SCZ) patients and relatives have deficits in early cortical sensory gating (SG) typically measured by suppression of electroencephalography-derived P50 event-related potentials (ERPs) in a conditioning-testing (S This pilot study in healthy humans assessed the SG effects of an α7 nAChR strategy combining CDP-choline with galantamine, a positive allosteric modulator (PAM) of nAChRs, aimed at increasing and prolonging nicotinic receptor activity. The combined effect of CDP-choline (500 mg) and galantamine (16 mg) on speech P50 gating indices rP50 (S In low suppressors, CDP-choline/galantamine (vs. placebo) improved rP50 and dP50 gating, and reduced S Findings from this pilot study with CDP-choline/galantamine in a healthy, SCZ-like surrogate deficient gating sample are consistent with the association of α7 nAChR mechanisms in SG impairment in SCZ and support further research trials with CDP-choline and galantamine targeting sensory processes.
Sections du résumé
BACKGROUND
Schizophrenia (SCZ) patients and relatives have deficits in early cortical sensory gating (SG) typically measured by suppression of electroencephalography-derived P50 event-related potentials (ERPs) in a conditioning-testing (S
AIMS
This pilot study in healthy humans assessed the SG effects of an α7 nAChR strategy combining CDP-choline with galantamine, a positive allosteric modulator (PAM) of nAChRs, aimed at increasing and prolonging nicotinic receptor activity.
METHODS
The combined effect of CDP-choline (500 mg) and galantamine (16 mg) on speech P50 gating indices rP50 (S
RESULTS
In low suppressors, CDP-choline/galantamine (vs. placebo) improved rP50 and dP50 gating, and reduced S
CONCLUSION
Findings from this pilot study with CDP-choline/galantamine in a healthy, SCZ-like surrogate deficient gating sample are consistent with the association of α7 nAChR mechanisms in SG impairment in SCZ and support further research trials with CDP-choline and galantamine targeting sensory processes.
Identifiants
pubmed: 30920339
doi: 10.1177/0269881119836217
doi:
Substances chimiques
Nicotinic Agonists
0
Nootropic Agents
0
Receptors, Nicotinic
0
alpha7 Nicotinic Acetylcholine Receptor
0
Galantamine
0D3Q044KCA
Cytidine Diphosphate Choline
536BQ2JVC7
Nicotine
6M3C89ZY6R
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
688-699Subventions
Organisme : CIHR
Pays : Canada